
1. curr opin rheumatol. 2010 may;22(3):278-83. doi: 10.1097/bor.0b013e3283368099.

interferon therapy rheumatic diseases: state-of-the-art 2010.

kötter i(1), hamuryudan v, oztürk ze, yazici h.

author information: 
(1)department internal medicine ii, university hospital, tübingen, germany.

purpose review: interferons natural glycoproteins antiviral,
antiproliferative immune regulatory functions. involved 
the pathogenesis certain autoimmune conditions also useful the
treatment rheumatologic disorders, notably behçet's syndrome.
recent findings: interferon alpha (ifnalpha) recommended severe eye 
involvement behçet's syndrome, especially significant drop 
visual acuity and/or retinal involvement. induce high rate complete
remission may also persist discontinuation. given early at
the beginning, interferon might effective ameliorating attacks of
familial mediterranean fever resistant colchicine treatment. combination
of pegylated ifnalpha ribavirin rituximab emerges novel and
promising treatment providing complete clinical response viral clearance in
hepatitis c virus-associated mixed cryoglobulinemia. limited data also suggest
that interferon may induce remissions churg-strauss patients fail to
respond conventional immunosuppressive treatment.
summary: among several rheumatologic diseases, ifnalpha found widespread
use behçet's syndrome hepatitis c virus-associated mixed cryoglobulinemia 
despite paucity formal studies. patients carefully monitored for
the frequent dose-dependent adverse effects.

doi: 10.1097/bor.0b013e3283368099 
pmid: 20061957  [indexed medline]

